Most metastatic-enriched cancer drivers had a cancer-type-specific enrichment, including well-established resistance gene drivers associated with anticancer therapies, such as AR and ESR1 alterations in patients with prostate and ER+ breast carcinomas treated with hormone deprivation therapies37,38 (Fig. 4b and Supplementary Note 2). This evidence concerns the gene AR and cancer.